Day One Biopharmaceuticals Inc (DAWN NASDAQ) stock market data APIs
$8.805
0.48(5.5%)
as of January 2, 2026
Try our APIs with
free plan!
Day One Biopharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Prev. Close
8.805
Open
9.2834
High
9.3967
Low
8.7114
52 wk Range
5.635-13.53
Market Cap
957 M
Shares Outstanding
103 M
Revenue
134 M
EPS
-0.19
Beta
-1.276
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Day One Biopharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Day One Biopharmaceuticals Inc data using free add-ons & libraries
Get Day One Biopharmaceuticals Inc Fundamental Data
Day One Biopharmaceuticals Inc Fundamental data includes:
- Net Revenue: 134 M
- EBITDA: -162 410 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Day One Biopharmaceuticals Inc News
New
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
BALA CYNWYD, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ...
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura O...
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib)
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) is one of the stocks that will double in 2026. On November 24, JonesTrading analyst Soumit Roy maintained a bullish stance on the company, with a Buy rati...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)
BALA CYNWYD, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
